» Articles » PMID: 31717414

Lipid Related Genes Altered in NASH Connect Inflammation in Liver Pathogenesis Progression to HCC: A Canonical Pathway

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2019 Nov 14
PMID 31717414
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Nonalcoholic steatohepatitis (NASH) is becoming a public health problem worldwide. While the number of research studies on NASH progression rises every year, sometime their findings are controversial. To identify the most important and commonly described findings related to NASH progression, we used an original bioinformatics, integrative, text-mining approach that combines PubMed database querying and available gene expression omnibus dataset. We have identified a signature of 25 genes that are commonly found to be dysregulated during steatosis progression to NASH and cancer. These genes are implicated in lipid metabolism, insulin resistance, inflammation, and cancer. They are functionally connected, forming the basis necessary for steatosis progression to NASH and further progression to hepatocellular carcinoma (HCC). We also show that five of the identified genes have genome alterations present in HCC patients. The patients with these genes associated to genome alteration are associated with a poor prognosis. In conclusion, using an integrative literature- and data-mining approach, we have identified and described a canonical pathway underlying progression of NASH. Other parameters (. polymorphisms) can be added to this pathway that also contribute to the progression of the disease to cancer. This work improved our understanding of the molecular basis of NASH progression and will help to develop new therapeutic approaches.

Citing Articles

Early Deregulation of Cholangiocyte NR0B2 During Primary Sclerosing Cholangitis.

Desterke C, Chung C, Pan D, Trauner M, Samuel D, Azoulay D Gastro Hep Adv. 2024; 2(1):49-62.

PMID: 39130146 PMC: 11307415. DOI: 10.1016/j.gastha.2022.07.023.


Constructing a prognostic model for hepatocellular carcinoma based on bioinformatics analysis of inflammation-related genes.

Li Y, Fang Y, Li D, Wu J, Huang Z, Liao X Front Med (Lausanne). 2024; 11:1420353.

PMID: 39055701 PMC: 11269197. DOI: 10.3389/fmed.2024.1420353.


Predicting Non-Alcoholic Steatohepatitis: A Lipidomics-Driven Machine Learning Approach.

Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Germanidis G, Gika H Int J Mol Sci. 2024; 25(11).

PMID: 38892150 PMC: 11172949. DOI: 10.3390/ijms25115965.


Molecular mechanisms in MASLD/MASH-related HCC.

Wang X, Zhang L, Dong B Hepatology. 2024; .

PMID: 38349726 PMC: 11323288. DOI: 10.1097/HEP.0000000000000786.


Lipid Metabolism in Metabolic-Associated Steatotic Liver Disease (MASLD).

Syed-Abdul M Metabolites. 2024; 14(1).

PMID: 38248815 PMC: 10818604. DOI: 10.3390/metabo14010012.


References
1.
Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

2.
Li L, Pilo G, Li X, Cigliano A, Latte G, Che L . Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. J Hepatol. 2015; 64(2):333-341. PMC: 4718802. DOI: 10.1016/j.jhep.2015.10.004. View

3.
Tiniakos D, Vos M, Brunt E . Nonalcoholic fatty liver disease: pathology and pathogenesis. Annu Rev Pathol. 2010; 5:145-71. DOI: 10.1146/annurev-pathol-121808-102132. View

4.
Li Z, Guan M, Lin Y, Cui X, Zhang Y, Zhao Z . Aberrant Lipid Metabolism in Hepatocellular Carcinoma Revealed by Liver Lipidomics. Int J Mol Sci. 2017; 18(12). PMC: 5751153. DOI: 10.3390/ijms18122550. View

5.
Zambon A, Gaj S, Ho I, Hanspers K, Vranizan K, Evelo C . GO-Elite: a flexible solution for pathway and ontology over-representation. Bioinformatics. 2012; 28(16):2209-10. PMC: 3413395. DOI: 10.1093/bioinformatics/bts366. View